Welch Allyn, Masimo integrate

Health IT companies Welch Allyn and Masimo have agreed on an integration strategy that will make the Masimo rainbow SET Pulse CO-Oximetry technology platform an offering in Welch Allyn's new product line.

This strategy will provide clinicians with a host of noninvasive, continuous measurements and patient monitoring capabilities, and will allow clinicians to add the Irvine, Calif.-based Masimo's measurements as optional software upgrades as the measurements become commercially available for use with the Welch Allyn patient monitor.

Masimo rainbow SET measurements provide physiological data that helps clinicians assess patients and detect adverse conditions. Pending regulatory clearance, Welch Allyn will announce the commercial availability of these rainbow SET parameters as they become legally available for use with its monitors, the Skaneateles Falls, N.Y.-based Welch Allyn stated.

The new Welch Allyn Connex Vital Signs Monitor (CVSM) is the first Welch Allyn monitor to integrate the Masimo rainbow SET technology. The CVSM incorporates Masimo's SpO2-enabled measurements and is capable of being field upgraded to add rainbow SET-based measurements as each parameter becomes commercially available for use with the CVSM, the companies added.

Around the web

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

One product is being pulled from the market, and the other is receiving updated instructions for use.

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?